Eptinezumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | CALCA, CALCB |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
Eptinezumab (formerly ALD403[1]) is an experimental drug being developed by Alder Biopharmaceuticals for the treatment of migraine. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.[2][3] It is in Phase III clinical trials as of August 2017.[4]
See also
- Other anti-migraine antibodies blocking the CGRP pathway
References
- ↑ http://investor.alderbio.com/releasedetail.cfm?releaseid=1001091
- ↑ Dodick, David W; Goadsby, Peter J; Silberstein, Stephen D; Lipton, Richard B; Olesen, Jes; Ashina, Messoud; Wilks, Kerri; Kudrow, David; Kroll, Robin; Kohrman, Bruce; Bargar, Robert; Hirman, Joe; Smith, Jeff (2014). "Safety and efficacy of eptinizumab, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet Neurology. 13 (11): 1100. PMID 25297013. doi:10.1016/S1474-4422(14)70209-1.
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 31 (1). 2017.
- ↑ "Pipeline". Alder Biopharmaceuticals.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.